Get the Stockscreener App
29.06
0.10%
-0.03
Smith Nephew Plc Adr stock is traded at $29.06, with a volume of 1.31M.
It is down -0.10% in the last 24 hours and up +4.53% over the past month.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
See More
Previous Close:
$29.09
Open:
$29.21
24h Volume:
1.31M
Relative Volume:
1.03
Market Cap:
$12.16B
Revenue:
$6.18B
Net Income/Loss:
$626.40M
P/E Ratio:
20.25
EPS:
1.435
Net Cash Flow:
$848.81M
1W Performance:
+6.68%
1M Performance:
+4.53%
6M Performance:
-14.10%
1Y Performance:
-18.85%
1-Day Range:
$28.94
$29.38
1-Week Range:
$27.23
$29.38
52-Week Range:
$26.12
$37.51
Smith Nephew Plc Adr Stock (SNN) Company Profile
Compare SNN vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
29.06 | 12.16B | 6.18B | 626.40M | 848.81M | 1.435 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-26 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-02-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-31-26 | Initiated | BTIG Research | Neutral |
| Aug-06-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-05-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-26 | Downgrade | Kepler | Buy → Hold |
| Dec-15-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-14-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Mar-12-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-24 | Downgrade | Berenberg | Buy → Hold |
| Nov-01-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-24 | Initiated | Deutsche Bank | Buy |
| Jun-05-24 | Upgrade | UBS | Neutral → Buy |
| Nov-28-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-03-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-31-23 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-13-23 | Initiated | Stifel | Hold |
| Aug-08-23 | Upgrade | UBS | Sell → Neutral |
| Apr-27-23 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-12-22 | Initiated | Citigroup | Buy |
| Nov-28-22 | Downgrade | UBS | Neutral → Sell |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-28-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-15-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-22 | Upgrade | Redburn | Sell → Neutral |
| Jun-09-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-18-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-01-20 | Initiated | Barclays | Overweight |
| Jul-29-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-21-19 | Initiated | Citigroup | Buy |
| Nov-12-19 | Initiated | Bernstein | Outperform |
| Jul-23-19 | Upgrade | Berenberg | Hold → Buy |
| Feb-08-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Jan-02-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-01-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-25-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-11-17 | Initiated | Canaccord Genuity | Buy |
| Feb-27-17 | Downgrade | Goldman | Buy → Neutral |
| Jan-19-17 | Initiated | HSBC Securities | Hold |
| Dec-08-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-06-16 | Downgrade | Berenberg | Buy → Hold |
| Feb-26-16 | Initiated | Cantor Fitzgerald | Hold |
View All
Smith Nephew Plc Adr Stock (SNN) Latest News
FTSE 100 Smith & Nephew (LSE:SN.): Outlook and Dividend - Kalkine Media
A Look at Smith & Nephew PLC (SNN) After 4.3% Gain -- GF Value $30.88 vs Price $29.09 - GuruFocus
Why Is Smith & Nephew (LSE:SN.) Stock Under Scrutiny After Cutting Its Sales Outlook? - Kalkine Media
SMITH & NEPHEW PLC (SN1N.MX) Q2 FY2026 earnings call transcript - Yahoo Finance
Smith & Nephew plc Completes the Pricing of USD 700,000,000 5.750% Notes Due 2036 - marketscreener.com
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets - Zacks Investment Research
A November 4 analyst call will follow Smith & Nephew (SNN)'s Q3 trading report. - Stock Titan
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal - GlobeNewswire Inc.
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo. - GlobeNewswire Inc.
A five-year trial found better knee pain relief with a cartilage implant than standard surgery. - Stock Titan
5.150% notes due 2027 are named in Smith & Nephew (NYSE: SNN)'s NYSE removal notice. - Stock Titan
Smith & Nephew PLC's Dividend Analysis - Yahoo Finance
Smith & Nephew stock hits 52-week low at 26.39 USD - Investing.com Nigeria
Smith & Nephew plc Announces Redemption Price of $350,000,000 5.150% Notes Due 2027 - marketscreener.com
837M shares carry votes at Smith & Nephew (SNN). Another 40.3M shares are held in treasury. - Stock Titan
The 5.150% notes due in 2027 will be redeemed by Smith & Nephew (SNN) on October 5. - Stock Titan
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care - Zacks Investment Research
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care - Yahoo Finance
AlphaValue/Baader Europe Downgrades Smith & Nephew to Add - marketscreener.com
Smith & Nephew: Estimates reset after guidance cut - marketscreener.com
Smith & Nephew (LSE:SN) Rolls Out EVOS PELVIC This Week: Can It Lift Its Orthopaedic Trauma Game? - Kalkine Media
Smith & Nephew stock faces a Q2 revenue miss - AD HOC NEWS
Smith and Nephew stock falls 0.24 percent ahead of the open - AD HOC NEWS
Smith & Nephew stock trades near its yearly low - AD HOC NEWS
Smith+Nephew Launches the New Evos? Pelvic Plating System - marketscreener.com
One system combines plates, screws and tools for complex pelvic fracture surgery - Stock Titan
Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System - markets.businessinsider.com
Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical case of LANDMARK◊ Total Knee System - Ortho Spine News
This shoulder implant has been used in more than 250,000 procedures. Smith+Nephew will showcase it. - Stock Titan
Smith & Nephew SNATS, Inc. (SNN) Stock Analysis: Unveiling a 19% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
New LSE share admission takes Smith & Nephew (NYSE: SNN) to 877,750,024 shares - Stock Titan
Smith & Nephew (NYSE: SNN) will retire $350M bond and delist it in October 2026 - Stock Titan
Oversubscribed bond buyback at Smith+Nephew (NYSE: SNN) leaves many tenders only partly filled - Stock Titan
Smith+Nephew (NYSE: SNN) sets price on $250M cash offer for its 2030 debt, but how much per $1,000 note? - Stock Titan
Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds - Moomoo
Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds - TradingView
Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds - Yahoo Finance
Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds - TradingView
Smith & Nephew stock slips to 52-week low as new USD bond reshapes debt profile - ad-hoc-news.de
Smith & Nephew (SNN) raises $700M in 5.75% debt - Stock Titan
Smith+Nephew (SNN) lines up $700M bond to replace 2030 notes - Stock Titan
Smith & Nephew (NYSE: SNN) lines up new bond to replace 2030 debt - Stock Titan
New 5.75% notes from Smith & Nephew (NYSE: SNN) run to 2036 - Stock Titan
Smith & Nephew stock declines as $250 million bond tender reshapes balance sheet - ad-hoc-news.de
Equity awards vest for Smith & Nephew (NYSE: SNN) strategy chief - Stock Titan
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m - Yahoo Finance
Smith & Nephew stock steadies as investors await fresh catalysts - ad-hoc-news.de
Orthopaedics chief at Smith & Nephew (NYSE: SNN) granted new share awards - Stock Titan
Trinity Biotech plcADR Peer Comparison – Compare with Others - valueresearchonline.com
Smith Nephew Plc Adr Stock (SNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):